<DOC>
	<DOCNO>NCT00952887</DOCNO>
	<brief_summary>The purpose study establish safe dose level ACE-031 healthy postmenopausal woman follow multiple dose administration . This study also evaluate ACE-031 effect muscle .</brief_summary>
	<brief_title>A Safety , Tolerability , Pharmacokinetic Pharmacodynamic Study ACE-031 Healthy Postmenopausal Women</brief_title>
	<detailed_description />
	<mesh_term>Atrophy</mesh_term>
	<mesh_term>Muscular Atrophy</mesh_term>
	<criteria>Postmenopausal Body mass index ( BMI ) ≥ 18.5 &lt; 32 . History malignancy , except excise treat basal cell carcinoma , cervical carcinoma insitu , ≤ 2 squamous cell carcinoma History clinically significant cardiac , endocrinologic , hematologic , hepatic , immunologic , metabolic , urologic , pulmonary , neurologic , dermatologic , psychiatric , renal , and/or major disease . History opportunistic infection ( e.g . invasive candidiasis pneumocystis pneumonia ) within 6 month prior screen serious local infection ( e.g. , cellulitis , abscess ) systemic infection ( e.g. , septicemia ) within 3 month prior screen . Surgery within 3 month prior Day 1 ( minor cosmetic dental procedure ) . Fever symptomatic viral bacterial infection within 7 day prior Day 1 . Donation significant loss blood within 2 month prior Day 1 . Hormone replacement therapy within 3 month prior Day 1 . Treatment erythropoiesis stimulate agent ( Epogen , Procrit , Aranesp , etc ) within 2 month prior Day 1 . Systemic glucocorticoid therapy within 6 month prior Day 1 . Treatment another investigational drug approve therapy investigational use within 1 month prior Day 1 . Previous treatment ACE031 .</criteria>
	<gender>Female</gender>
	<minimum_age>45 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>March 2011</verification_date>
</DOC>